ACADIA Pharmaceuticals Inc. (ACAD)

26.72
0.51 1.87
NASDAQ : Health Technology
Prev Close 27.23
Open 27.40
Day Low/High 26.63 / 27.40
52 Wk Low/High 12.77 / 28.67
Volume 574.29K
Avg Volume 1.02M
Exchange NASDAQ
Shares Outstanding 144.17M
Market Cap 3.93B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ACADIA Pharmaceuticals To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

ACADIA Pharmaceuticals To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present Phase 2 CLARITY Results For Pimavanserin As An Adjunctive Treatment In Major Depressive Disorder At The 2019 American Psychiatric Association Annual Meeting

ACADIA Pharmaceuticals To Present Phase 2 CLARITY Results For Pimavanserin As An Adjunctive Treatment In Major Depressive Disorder At The 2019 American Psychiatric Association Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it will present data from...

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2019

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for...

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program With Pimavanserin As Adjunctive Treatment For Major Depressive Disorder

ACADIA Pharmaceuticals Initiates Phase 3 CLARITY Program With Pimavanserin As Adjunctive Treatment For Major Depressive Disorder

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the initiation of...

ACADIA Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

ACADIA Pharmaceuticals To Announce First Quarter 2019 Financial Results On May 1, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Supports Parkinson's Disease Awareness Month And World Parkinson's Day With Local Educational Initiatives And Community Events Across The Country

ACADIA Pharmaceuticals Supports Parkinson's Disease Awareness Month And World Parkinson's Day With Local Educational Initiatives And Community Events Across The Country

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced support of several...

ACADIA Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 9, 2019

ACADIA Pharmaceuticals To Present At The 18th Annual Needham Healthcare Conference On April 9, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer (Photo: Business Wire)

Elena Ridloff, CFA, Executive Vice President, Chief Financial Officer (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the promotion of...

Positive Phase 2 Study Results Of Trofinetide In Pediatric Rett Syndrome Published In Neurology, The Medical Journal Of The American Academy Of Neurology

Positive Phase 2 Study Results Of Trofinetide In Pediatric Rett Syndrome Published In Neurology, The Medical Journal Of The American Academy Of Neurology

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Neuren Pharmaceuticals Limited (ASX: NEU), and Rettsyndrome.

ACADIA Pharmaceuticals To Present At The Cowen And Company 39th Annual Health Care Conference On March 11, 2019

ACADIA Pharmaceuticals To Present At The Cowen And Company 39th Annual Health Care Conference On March 11, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ACADIA Pharmaceuticals To Present At The 8th Annual Leerink Partners Global Healthcare Conference On February 28, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results On February 26, 2019

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results On February 26, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 9, 2019

ACADIA Pharmaceuticals To Present At The 37th Annual J.P. Morgan Healthcare Conference On January 9, 2019

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the closing of its...

Berkshire Hathaway, Oneok, FNB Corp.: 'Mad Money' Lightning Round

Berkshire Hathaway, Oneok, FNB Corp.: 'Mad Money' Lightning Round

Berkshire Hathaway, Oneok, FNB Corp., Axon Enterprises, Copa Holdings, Acadia Pharamaceuticals, Delta Airlines and more.

Fed Fuels This Rally: Cramer's 'Mad Money' Recap (Wednesday 11/28/18)

Fed Fuels This Rally: Cramer's 'Mad Money' Recap (Wednesday 11/28/18)

Jim Cramer says if we have a slowdown, don't blame Powell and the Fed. Instead, keep your eyes on the G-20 and trade issues.

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Prices Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the pricing of an...

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that it intends to...

Interesting ACAD Put And Call Options For January 2019

Interesting ACAD Put And Call Options For January 2019

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the January 2019 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new January 2019 contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Announces Positive Top-line Results From Phase 2 CLARITY Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder (MDD)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from CLARITY, a randomized, double-blind, placebo-controlled, multi-center, sequential parallel comparison design (SPCD) study in major depressive disorder (MDD).

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Announces Executive Leadership Change

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that Todd S.

Interesting ACAD Put And Call Options For June 2019

Interesting ACAD Put And Call Options For June 2019

Investors in Acadia Pharmaceuticals Inc saw new options become available this week, for the June 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Dropbox, XPO Logistics, Ford Motor: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dropbox, XPO Logistics, Ford Motor Co., Acadia Pharmaceuticals, Avalara, and more.

TheStreet Quant Rating: D (Sell)